Esperion Therapeutics, Inc. · NASDAQ:ESPR

Esperion Therapeutics — Investor Presentation (October 2025)

26 slides from Esperion Therapeutics's investor presentation, Oct 7, 2025

1. Slide 1: Esperion Corporate Presentation

   Esperion Corporate Presentation © 2025 Esperion Therapeutics, Inc. All rights reserved. October 2025

2. Slide 2: Forward-looking Statements & Disclosures

   2 © 2025 Esperion Therapeutics, Inc. All rights reserved. Forward-looking Statements & Disclosures This pre s e ntation c ontains forward-looking s tate me nts of Es pe rion The rape utic s , Inc . (“Es pe rion,” “we ,” or “our”) that are made purs uant to the s afe harbor provis ions of the fe de r

3. Slide 3: Clear Strategic Plan for Success

   Clear Strategic Plan for Success © 2025 Esperion Therapeutics, Inc. All rights reserved. 3 Expand Bempedoic Acid Franchise Globally • Key ANDA settlements provide the potential to secure additional years of exclusivity, extending blockbuster revenue potential • Settlement agreements for April 19, 20

4. Slide 4: Strategic Priorities

   Strategic Priorities 4 © 2025 Esperion Therapeutics, Inc. All rights reserved. Expand Bempedoic Acid Franchise Globally • Invest in targeted marketing initiatives to accelerate physician adoption and broaden patient access • Expand reach of sales team through targeted territory additions and enhance

5. Slide 5: Financial Highlights

   Financial Highlights 5 © 2025 Esperion. All Rights Reserved – Do not copy or distribute. 0 10 20 30 40 50 60 70 80 90 Q1 2025 Q2 2025 65.0 Total Net Revenue (in $MM) +27% 0 5 10 15 20 25 30 35 40 45 Q1 2025 Q2 2025 35.0 U.S. Product Revenue (in $MM) +15% 0 5 10 15 20 25 30 35 40 Q1 2025 Q2 2025 30.1

6. Slide 6: Strong Prescription Trend and Increasing Physician Adoption

   - 20,000 40,000 60,000 80,000 100,000 120,000 140,000 160,000 180,000 200,000 220,000 240,000 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Strong Prescription Trend and Increasing Physician Adoption Continue to Drive Durable Revenue Growth © 2025 Esperion Therapeutics, Inc. All rights

7. Slide 7: Driving U.S. and Global Growth and Reaching Profitability

   Driving U.S. and Global Growth and Reaching Profitability

8. Slide 8: Despite Statins, an Ongoing Medical Need for Oral Therapies Remains

   1. Shen M, et al. J Am Heart Assoc, 2022;11:3026075. 2. Metser G. et al. Am J Cardiol. 2021;161:36-41 . 3.Allen JM, et al. Circulation. 2019;140:A12904. 4. Yang Y, et al. Circulation. 2021;144:A10434. 5. Wong ND, et al. J Clin Lipid.2016;10:1109-1118. 6. Cheeley MK, et al. J Clin Lipidol. 2022 Jul-A

9. Slide 9: Significant and Growing U.S. Market Opportunity

   1. Allen JM, et al. Circulation. 2019;140:A12904. 2. Shen M, Nargesi AA, et al. J Am Heart Assoc. 2022;11:e026075. 3. Yang Y, et al. Circulation. 2021;144:A10434. 4. Wong ND, et al. J Clin Lipidology. 2016;10:1109-1118. 5. Bytyci I, et al. Eur Heart J. 2022;00:1-16. 6. Total U.S. Resident Population

10. Slide 10: Bempedoic Acid Received 1a Recommendation in Updated ESC/EAS Guidelines

    Bempedoic Acid Received 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias 10 © 2025 Esperion Therapeutics, Inc. All rights reserved. • Bempedoic acid was the only new non-statin included with LDL-C and CV risk reduction data. • First time a guideline has given a Level

11. Slide 11: Filling the Treatment Gap: Our Breakthrough in LDL-C Management

    Filling the Treatment Gap: Our Breakthrough in LDL-C Management © 2025 Esperion Therapeutics, Inc. All rights reserved. 11 Ezetimibe STATINS NON-STATIN THERAPIES • Mostly generic • First-line, widely used • Combinable for incremental LDL-lowering • 25-55% drops in LDL-C CV Risk Reduction Indication

12. Slide 12: The Next Step in Cardiovascular Risk Reduction

    The Next Step in Cardiovascular Risk Reduction 12 CV Risk Reduction 27% Nonfatal MI Coronary Revascularization 19% CLEAR Outcomes Primary Prevention* 32% MACE-4 (nonfatal MI, coronary revascularization, nonfatal stroke, or CV death) LDL-C Reduction 38% Not activated in skeletal muscle Does not raise

13. Slide 13: Strengthening Access and Driving Growth

    Strengthening Access and Driving Growth 13 © 2025 Esperion Therapeutics, Inc. All rights reserved. • 10% increase in total retail prescription equivalents vs. Q1 2025 • Now over 28,000 total HCPs • 23% of prescriptions written by physicians with only digital touchpoints • 38% of new writer prescript

14. Slide 14: Strategic Partnerships Driving Billion $ Global Opportunity

    Strategic Partnerships Driving Billion $ Global Opportunity © 2025 Esperion Therapeutics, Inc. All rights reserved. 14 Partner Daiichi Sankyo Europe Asia & South America Daiichi Sankyo Co., Ltd. Otsuka Pharmaceutical Co., Ltd. Agreement Terms Neopharm Israel HLS Therapeutics Tiered royalties and add

15. Slide 15: Pipeline Advancement

    =SPERION Pipeline Advancement

16. Slide 16: Proven Science, Innovative Pipeline

    Renal Diseases To Be Announced Primary Sclerosing Cholangitis (PSC) IND: 2026 PRODUCT/PROGRAM EXPLORATORY LEAD ID LEAD OPTIMIZATION PRECLINICAL DEVELOPMENT CLINICAL DEVELOPMENT APPROVED / COMMERCIAL MILESTONES Proven Science, Innovative Pipeline 16 © 2025 Esperion Therapeutics, Inc. All rights reser

17. Slide 17: Oral Triple Combination

    Oral Triple Combination © 2025 Esperion Therapeutics, Inc. All rights reserved. 17 1. Product in development, not approved, LDL-C data based on literature evaluating co administered products (Rubino et.al Atherosclerosis 320 (2021) 122-128, Mahajan et.al. J. Clin. Lipidology (2004), Vol 18 (5) e867-

18. Slide 18: PSC: High Unmet Medical Need Driving Significant Market Opportunity

    PSC: High Unmet Medical Need Driving Significant Market Opportunity 18 © 2025 Esperion Therapeutics, Inc. All rights reserved. 2024 Diagnosed Prevalence of PSC US EU 1. Bakhshi Z, et al. J Gastroenterol. 2020 May;55(5):523-532.; 2. Nguyen A, et al. Front Gastroenterol (Lausanne). 2022;1:1076788.; 3.

19. Slide 19: Development Timeline

    Development Timeline 2025 2026 Early 2030’s Pre-IND Interactions with FDA Pre-Clinical IND-Enabling Studies IND Filing Phase 1 Clinical Studies Commercialization / Market Launch FDA: Food and Drug Administration IND Enabling Clinical Development Registration/Launch Candidate Nomination Discovery 19

20. Slide 20: Experienced Leaders, Breakthrough Results

    Experienced Leaders, Breakthrough Results 20 © 2025 Esperion Therapeutics, Inc. All rights reserved. Sheldon Koenig PRESIDENT AND CHIEF EXECUTIVE OFFICER Glenn Brame CHIEF TECHNICAL OPERATIONS OFFICER Betty Jean Swartz CHIEF BUSINESS OFFICER Ben Looker, Esq. GENERAL COUNSEL Ben Halladay CHIEF FINANC

21. Slide 21: Appendix

    =SPERION Appendix

22. Slide 22: Significantly Differentiated from Potential Competitors

    Significantly Differentiated from Potential Competitors © 2025 Esperion Therapeutics, Inc. All rights reserved. 22 Commercially Available Bempedoic Acid1 (alone and in combination with ezetimibe) CV Risk Reduction MACE-4: -13% MACE-3: -15% CV Risk Reduction in Primary Prevention MACE-4: -32% MACE-3:

23. Slide 23: Significantly Differentiated from Potential Competitors cont.

    Significantly Differentiated from Potential Competitors cont. © 2025 Esperion Therapeutics, Inc. All rights reserved. 23 Commercially Available Bempedoic Acid1 (alone and in combination with ezetimibe) CV Risk Reduction MACE-4: -13% MACE-3: -15% Not available (Q3 2029*) PCSK9i [enlicitide decanoate

24. Slide 24: Important Safety Information

    Important Safety Information

25. Slide 25: NEXLETOL (bempedoic acid) Important Safety Information

    NEXLETOL® (bempedoic acid) Important Safety Information 25 © 2025 Esperion Therapeutics, Inc. All rights reserved. • NEXLIZET is indicated: • The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who ar

26. Slide 26: NEXLIZET (bempedoic acid and ezetimibe) Important Safety Information

    NEXLIZET® (bempedoic acid and ezetimibe) Important Safety Information 26 © 2025 Esperion Therapeutics, Inc. All rights reserved. • NEXLIZET is indicated: • The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of myocardial infarction and coronary revascularization in

Esperion Therapeutics — Investor Presentation (October 2025) on 6ix